PGAM1 Inhibitors and Methods Related Thereto

Abstract

In certain embodiments, the disclosure relates to methods of treating or preventing a PGAM1 mediated condition such as cancer or tumor growth comprising administering an effective amount of PGAM1 inhibitor, for example, an anthracene-9,10-dione derivative to a subject in need thereof. In certain embodiments, the disclosure relates to methods of treating or preventing cancer, such as lung cancer, head and neck cancer, and leukemia, comprising administering a therapeutically effective amount of a pharmaceutical composition comprising a compound disclosed herein or pharmaceutically acceptable salt to a subject in need thereof.

1 . An antibody to PGAM1 phospho-Y26 epitope. 
     
     
         2 . The antibody of  claim 1 , wherein the antibody is a human chimera or humanized antibody. 
     
     
         3 . A pharmaceutical composition comprising an antibody that binds PGAM1 phospho-Y26 epitope and a pharmaceutically acceptable excipient. 
     
     
         4 . A method of treatment of cancer comprising administering an effective amount of an antibody that binds the PGAM1 to a subject in need thereof. 
     
     
         5 . The method of  claim 1  wherein the antibody binds PGAM1 residue Tyr26. 
     
     
         6 . The method of  claim 1  wherein the antibody binds PGAM1 phospho-tyrosine at residue Tyr26. 
     
     
         7 . The method of  claim 4  wherein the antibody is administered in combination with another anti-cancer agent.